Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects

Science Translational Medicine

Volumn 9, Issue 371, 2017, Pages

  Kublin, James G ^a,b,c   Mikolajczak, Sebastian A ^a   Sack, Brandon K ^a   Fishbaugher, Matt E ^a   Seilie, Annette ^b   Shelton, Lisa ^a   VonGoedert, Tracie ^a   Firat, Melike ^a   Magee, Sara ^a   Fritzen, Emma ^a   Betz, Will ^a   Kain, Heather S ^a   Dankwa, Dorender A ^a   Steel, Ryan W J ^a   Vaughan, Ashley M ^a   Sather, D Noah ^a   Murphy, Sean C ^a,b   Kappe, Stefan H I ^a,b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; IMMUNOGLOBULIN G; LIVE VACCINE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; APPLICATION SITE DISCOLORATION; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE SWELLING; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENE DELETION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALARIA FALCIPARUM; MALE; MICROBIAL ATTENUATION; MICROBIAL GENE; MOSQUITO BITE; MOUSE; NONHUMAN; NORMAL HUMAN; P36 GENE; P52 GENE; PLASMODIUM FALCIPARUM; SAP1 GENE; SPOROZOITE; TRANSGENIC ORGANISM; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CLINICAL TRIAL; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; FEMALE; GENE DELETION; GENETIC ENGINEERING; HUMANS; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SPOROZOITES; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 85010685235     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad9099     Document Type: Article

References (42)

1. World Health Organization, World Malaria Report 2015 (World Health Organization, 2015).
2. RTS, S Clinical Trials Partnership, S. T. Agnandji, B. Lell, J. F. Fernandes, B. P. Abossolo, B. G. Methogo, A. L. Kabwende, A. A. Adegnika, B. Mordmüller, S. Issifou, P. G. Kremsner, J. Sacarlal, P. Aide, M. Lanaspa, J. J. Aponte, S. Machevo, S. Acacio, H. Bulo, B. Sigauque, E. Macete, P. Alonso, S. Abdulla, N. Salim, R. Minja, M. Mpina, S. Ahmed, A. M. Ali, A. T. Mtoro, A. S. Hamad, P. Mutani, M. Tanner, H. Tinto, U. D'Alessandro, H. Sorgho, I. Valea, B. Bihoun, I. Guiraud, B. Kaboré, O. Sombié, R. T. Guiguemdé, J. B. Ouédraogo, M. J. Hamel, S. Kariuki, M. Oneko, C. Odero, K. Otieno, N. Awino, M. McMorrow, V. Muturi-Kioi, K. F. Laserson, L. Slutsker, W. Otieno, L. Otieno, N. Otsyula, S. Gondi, A. Otieno, V. Owira, E. Oguk, G. Odongo, J. B. Woods, B. Ogutu, P. Njuguna, R. Chilengi, P. Akoo, C. Kerubo, C. Maingi, T. Lang, A. Olotu, P. Bejon, K. Marsh, G. Mwambingu, S. Owusu-Agyei, K. P. Asante, K. Osei-Kwakye, O. Boahen, D. Dosoo, I. Asante, G. Adjei, E. Kwara, D. Chandramohan, B. Greenwood, J. Lusingu, S. Gesase, A. Malabeja, O. Abdul, C. Mahende, E. Liheluka, L. Malle, M. Lemnge, T. G. Theander, C. Drakeley, D. Ansong, T. Agbenyega, S. Adjei, H. O. Boateng, T. Rettig, J. Bawa, J. Sylverken, D. Sambian, A. Sarfo, A. Agyekum, F. Martinson, I. Hoffman, T. Mvalo, P. Kamthunzi, R. Nkomo, T. Tembo, G. Tegha, M. Tsidya, J. Kilembe, C. Chawinga, W. R. Ballou, J. Cohen, Y. Guerra, E. Jongert, D. Lapierre, A. Leach, M. Lievens, O. Ofori-Anyinam, A. Olivier, J. Vekemans, T. Carter, D. Kaslow, D. Leboulleux, C. Loucq, A. Radford, B. Savarese, D. Schellenberg, M. Sillman, P. Vansadia, A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284-2295 (2012).
3. A. Olotu, G. Fegan, J. Wambua, G. Nyangweso, K. O. Awuondo, A. Leach, M. Lievens, D. Leboulleux, P. Njuguna, N. Peshu, K. Marsh, P. Bejon, Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 368, 1111-1120 (2013).
4. R. S. Nussenzweig, J. Vanderberg, H. Most, C. Orton, Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216, 160-162 (1967).
5. S. L. Hoffman, L. M. L. Goh, T. C. Luke, I. Schneider, T. P. Le, D. L. Doolan, J. Sacci, P. de la Vega, M. Dowler, C. Paul, D. M. Gordon, J. A. Stoute, L. W. Church, M. Sedegah, D. G. Heppner, W. R. Ballou, T. L. Richie, Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164 (2002).
6. M. Roestenberg, M. McCall, J. Hopman, J. Wiersma, A. J. F. Luty, G. J. van Gemert, M. van de Vegte-Bolmer, B. van Schaijk, K. Teelen, T. Arens, L. Spaarman, Q. de Mast, W. Roeffen, G. Snounou, L. Rénia, A. van der Ven, C. C. Hermsen, R. Sauerwein, Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468-477 (2009).
7. S. M. Khan, C. J. Janse, S. H. I. Kappe, S. A. Mikolajczak, Genetic engineering of attenuated malaria parasites for vaccination. Curr. Opin. Biotechnol. 23, 908-916 (2012).
8. E. M. Bijker, S. Borrmann, S. H. Kappe, B. Mordmüller, B. K. Sack, S. M. Khan, Novel approaches to whole sporozoite vaccination against malaria. Vaccine 33, 7462-7468 (2015).
9. S. A. Mikolajczak, V. Lakshmanan, M. Fishbaugher, N. Camargo, A. Harupa, A. Kaushansky, A. N. Douglass, M. Baldwin, J. Healer, M. O'Neill, T. Phuong, A. Cowman, S. H. I. Kappe, A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol. Ther. 22, 1707-1715 (2014).
10. A. Kaushansky, L. S. Austin, S. A. Mikolajczak, F. Y. Lo, J. L. Miller, A. N. Douglass, N. Arang, A. M. Vaughan, M. J. Gardner, S. H. I. Kappe, Susceptibility to Plasmodium yoelii preerythrocytic infection in BALB/c substrains is determined at the point of hepatocyte invasion. Infect. Immun. 83, 39-47 (2015).
11. M. Spring, J. Murphy, R. Nielsen, M. Dowler, J. W. Bennett, S. Zarling, J. Williams, P. de la Vega, L. Ware, J. Komisar, M. Polhemus, T. L. Richie, J. Epstein, C. Tamminga, I. Chuang, N. Richie, M. O'Neil, D. G. Heppner, J. Healer, M. O'Neill, H. Smithers, O. C. Finney, S. A. Mikolajczak, R. Wang, A. Cowman, C. Ockenhouse, U. Krzych, S. H. Kappe, First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31, 4975-4983 (2013).
12. H. Azuma, N. Paulk, A. Ranade, C. Dorrell, M. Al-Dhalimy, E. Ellis, S. Strom, M. A. Kay, M. Finegold, M. Grompe, Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat. Biotechnol. 25, 903-910 (2007).
13. A. M. Vaughan, S. A. Mikolajczak, E. M. Wilson, M. Grompe, A. Kaushansky, N. Camargo, J. Bial, A. Ploss, S. H. I. Kappe, Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J. Clin. Invest. 122, 3618-3628 (2012).
14. B. K. Sack, J. L. Miller, A. M. Vaughan, A. Douglass, A. Kaushansky, S. Mikolajczak, A. Coppi, G. Gonzalez-Aseguinolaza, M. Tsuji, F. Zavala, P. Sinnis, S. H. Kappe, J. H. Adams, Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect. Immun. 82, 808-817 (2014).
15. A. M. Vaughan, S. A. Mikolajczak, N. Camargo, V. Lakshmanan, M. Kennedy, S. E. Lindner, J. L. Miller, J. C. C. Hume, S. H. I. Kappe, A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle. Mol. Biochem. Parasitol. 186, 143-147 (2012).
16. E. M. Riley, V. A. Stewart, Immune mechanisms in malaria: New insights in vaccine development. Nat. Med. 19, 168-178 (2013).
17. R. Wang, J. D. Smith, S. H. I. Kappe, Advances and challenges in malaria vaccine development. Expert Rev. Mol. Med. 11, e39 (2009).
18. S. H. Hodgson, K. J. Ewer, C. M. Bliss, N. J. Edwards, T. Rampling, N. A. Anagnostou, E. de Barra, T. Havelock, G. Bowyer, I. D. Poulton, S. de Cassan, R. Longley, J. J. Illingworth, A. D. Douglas, P. B. Mange, K. A. Collins, R. Roberts, S. Gerry, E. Berrie, S. Moyle, S. Colloca, R. Cortese, R. E. Sinden, S. C. Gilbert, P. Bejon, A. M. Lawrie, A. Nicosia, S. N. Faust, A. V. S. Hill, Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J. Infect. Dis. 211, 1076-1086 (2015).
19. J. A. Regules, J. F. Cummings, C. F. Ockenhouse, The RTS, S vaccine candidate for malaria. Expert Rev. Vaccines 10, 589-599 (2011).
20. S. L. Hoffman, P. F. Billingsley, E. James, A. Richman, M. Loyevsky, T. Li, S. Chakravarty, A. Gunasekera, R. Chattopadhyay, M. Li, R. Stafford, A. Ahumada, J. E. Epstein, M. Sedegah, S. Reyes, T. L. Richie, K. E. Lyke, R. Edelman, M. B. Laurens, C. V. Plowe, B. K. Sim, Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6, 97-106 (2010).
21. R. A. Seder, L.-J. Chang, M. E. Enama, K. L. Zephir, U. N. Sarwar, I. J. Gordon, L. A. Holman, E. R. James, P. F. Billingsley, A. Gunasekera, A. Richman, S. Chakravarty, A. Manoj, S. Velmurugan, M. Li, A. J. Ruben, T. Li, A. G. Eappen, R. E. Stafford, S. H. Plummer, C. S. Hendel, L. Novik, P. J. M. Costner, F. H. Mendoza, J. G. Saunders, M. C. Nason, J. H. Richardson, J. Murphy, S. A. Davidson, T. L. Richie, M. Sedegah, A. Sutamihardja, G. A. Fahle, K. E. Lyke, M. B. Laurens, M. Roederer, K. Tewari, J. E. Epstein, B. K. L. Sim, J. E. Ledgerwood, B. S. Graham, S. L. Hoffman; VRC 312 Study Team, Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359-1365 (2013).
22. A. G. Maier, J. A. M. Braks, A. P. Waters, A. F. Cowman, Negative selection using yeast cytosine deaminase/uracil phosphoribosyl transferase in Plasmodium falciparum for targeted gene deletion by double crossover recombination. Mol. Biochem. Parasitol. 150, 118-121 (2006).
23. M. T. O'Neill, T. Phuong, J. Healer, D. Richard, A. F. Cowman, Gene deletion from Plasmodium falciparum using FLP and Cre recombinases: Implications for applied site-specific recombination. Int. J. Parasitol. 41, 117-123 (2011).
24. M. J. Gardner, N. Hall, E. Fung, O. White, M. Berriman, R. W. Hyman, J. M. Carlton, A. Pain, K. E. Nelson, S. Bowman, I. T. Paulsen, K. James, J. A. Eisen, K. Rutherford, S. L. Salzberg, A. Craig, S. Kyes, M.-S. Chan, V. Nene, S. J. Shallom, B. Suh, J. Peterson, S. Angiuoli, M. Pertea, J. Allen, J. Selengut, D. Haft, M. W. Mather, A. B. Vaidya, D. M. A. Martin, A. H. Fairlamb, M. J. Fraunholz, D. S. Roos, S. A. Ralph, G. I. McFadden, L. M. Cummings, G. M. Subramanian, C. Mungall, J. C. Venter, D. J. Carucci, S. L. Hoffman, C. Newbold, R. W. Davis, C. M. Fraser, B. Barrell, Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511 (2002).
25. S. A. Mikolajczak, H. Silva-Rivera, X. Peng, A. S. Tarun, N. Camargo, V. Jacobs-Lorena, T. M. Daly, L. W. Bergman, P. de la Vega, J. Williams, A. S. I. Aly, S. H. I. Kappe, Distinct malaria parasite sporozoites reveal transcriptional changes that cause differential tissue infection competence in the mosquito vector and mammalian host. Mol. Cell. Biol. 28, 6196-6207 (2008).
26. K. M. VanBuskirk, M. T. O'Neill, P. De La Vega, A. G. Maier, U. Krzych, J. Williams, M. G. Dowler, J. B. Sacci Jr., N. Kangwanrangsan, T. Tsuboi, N. M. Kneteman, D. G. Heppner Jr., B. A. Murdock, S. A. Mikolajczak, A. S. I. Aly, A. F. Cowman, S. H. I. Kappe, Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc. Natl. Acad. Sci. U.S.A. 106, 13004-13009 (2009).
27. D. L. Medica, P. Sinnis, Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect. Immun. 73, 4363-4369 (2005).
28. Y. Jin, C. Kebaier, J. Vanderberg, Direct microscopic quantification of dynamics of Plasmodium berghei sporozoite transmission from mosquitoes to mice. Infect. Immun. 75, 5532-5539 (2007).
29. P. L. Felgner, M. Roestenberg, L. Liang, C. Hung, A. Jain, J. Pablo, R. Nakajima-Sasaki, D. Molina, K. Teelen, C. C. Hermsen, R. Sauerwein, Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci. Rep. 3, 3549 (2013).
30. N. W. Schmidt, N. S. Butler, V. P. Badovinac, J. T. Harty, Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLOS Pathog. 6, e1000998 (2010).
31. N. S. Butler, N. W. Schmidt, A. M. Vaughan, A. S. Aly, S. H. I. Kappe, J. T. Harty, Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9, 451-462 (2011).
32. K. E. Swearingen, S. E. Lindner, L. Shi, M. J. Shears, A. Harupa, C. S. Hopp, A. M. Vaughan, T. A. Springer, R. L. Moritz, S. H. I. Kappe, P. Sinnis, Interrogating the Plasmodium sporozoite surface: Identification of surface-exposed proteins and demonstration of glycosylation on CSP and TRAP by mass spectrometry-based proteomics. PLOS Pathog. 12, e1005606 (2016).
33. O. Jobe, J. Lumsden, A.-K. Mueller, J. Williams, H. Silva-Rivera, S. H. I. Kappe, R. J. Schwenk, K. Matuschewski, U. Krzych, Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-g-producing CD8+ T cells. J. Infect. Dis. 196, 599-607 (2007).
34. J. M. Lumsden, R. J. Schwenk, L. E. Rein, P. Moris, M. Janssens, O. Ofori-Anyinam, J. Cohen, K. E. Kester, D. G. Heppner, U. Krzych, Protective immunity induced with the RTS, S/AS vaccine is associated with IL-2 and TNF-a producing effector and central memory CD4+ T cells. PLOS ONE 6, e20775 (2011).
35. D. Berenzon, R. J. Schwenk, L. Letellier, M. Guebre-Xabier, J. Williams, U. Krzych, Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells. J. Immunol. 171, 2024-2034 (2003).
36. A. K. Talley, S. A. Healy, O. C. Finney, S. C. Murphy, J. Kublin, C. J. Salas, S. Lundebjerg, P. Gilbert, W. C. Van Voorhis, J. Whisler, R. Wang, C. F. Ockenhouse, D. G. Heppner, S. H. Kappe, P. E. Duffy, Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge. PLOS ONE 9, e109654 (2014).
37. M. B. Laurens, C. J. Duncan, J. E. Epstein, A. V. Hill, J. L. Komisar, K. E. Lyke, C. F. Ockenhouse, T. L. Richie, M. Roestenberg, R. W. Sauerwein, M. D. Spring, A. K. Talley, V. S. Moorthy; Consensus Group on Design of Clinical Trials of Controlled Human Malaria Infection, A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine 30, 5302-5304 (2012).
38. S. C. Murphy, G. Daza, M. Chang, R. Coombs, Laser cutting eliminates nucleic acid cross-contamination in dried-blood-spot processing. J. Clin. Microbiol. 50, 4128-4130 (2012).
39. G. Sellhorn, Z. Caldwell, C. Mineart, L. Stamatatos, Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. Vaccine 28, 430-436 (2009).
40. S. Carbonetti, B. G. Oliver, J. Glenn, L. Stamatatos, D. N. Sather, Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies. PLOS ONE 9, e86905 (2014).
41. A. Kaushansky, N. Rezakhani, H. Mann, S. H. I. Kappe, Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites. Mol. Biochem. Parasitol. 183, 100-103 (2012).
42. O. C. Finney, G. J. Keitany, H. Smithers, A. Kaushansky, S. Kappe, R. Wang, Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites. Vaccine 32, 2135-2138 (2014).